Viewing data from:

IMAAVY

BLA

NIPOCALIMAB-AAHU | B761430 | JANSSEN BIOTECH

2 products0 Purple Book patents

Biologic LOEProtected

Estimated date when biosimilar competition may begin

April 29, 2037(3953 days remaining)

Regulatory Exclusivities

Type	Expiry	Status	Source
12-Year BPCIA	Apr. 29, 2037	Active	Computed

Purple Book Patents

No listed patents in Purple Book.

Estimated Patent LOE

Jul. 17, 20456954 days remaining

Based on latest discovered patent 12365743(composition) · relevance 85/100

Estimate based on AI-discovered patents. No patents are officially listed in the Purple Book for this product.

Discovered Patents

View all 194 patents →

Top 50 of 194 AI-discovered patents by relevance.

Composition

(33)

95/1006835823Grant: 2004-12-28 | Exp: 2024-12-23

95/1007166285Grant: 2007-01-23 | Exp: 2027-01-18

92/1009939452Grant: 2018-04-10 | Exp: 2038-04-05

92/1007887807Grant: 2011-02-15 | Exp: 2031-02-10

92/10011359029Grant: 2022-06-14 | Exp: 2042-06-09

92/1009676848Grant: 2017-06-13 | Exp: 2037-06-08

92/1007279157Grant: 2007-10-09 | Exp: 2027-10-04

92/1006790444Grant: 2004-09-14 | Exp: 2024-09-09

92/1007070775Grant: 2006-07-04 | Exp: 2026-06-29

90/1007160995Grant: 2007-01-09 | Exp: 2027-01-04

90/1008084233Grant: 2011-12-27 | Exp: 2031-12-22

88/1009850310Grant: 2017-12-26 | Exp: 2037-12-21

88/10011236155Grant: 2022-02-01 | Exp: 2042-01-27

88/1007101674Grant: 2006-09-05 | Exp: 2026-08-31

85/1006902734Grant: 2005-06-07 | Exp: 2025-06-02

85/10011365244Grant: 2022-06-21 | Exp: 2042-06-16

85/10012065488Grant: 2024-08-20 | Exp: 2044-08-15

85/1008617894Grant: 2013-12-31 | Exp: 2033-12-26

85/10010934328Grant: 2021-03-02 | Exp: 2041-02-25

85/1008415291Grant: 2013-04-09 | Exp: 2033-04-04

85/10011725194Grant: 2023-08-15 | Exp: 2043-08-10

85/1007179893Grant: 2007-02-20 | Exp: 2027-02-15

85/1008703141Grant: 2014-04-22 | Exp: 2034-04-17

85/1007560247Grant: 2009-07-14 | Exp: 2029-07-09

85/10011149094Grant: 2021-10-19 | Exp: 2041-10-14

85/10012365743Grant: 2025-07-22 | Exp: 2045-07-17

85/10010562968Grant: 2020-02-18 | Exp: 2040-02-13

82/10012077592Grant: 2024-09-03 | Exp: 2044-08-29

80/10011844766Grant: 2023-12-19 | Exp: 2043-12-14

80/10011096998Grant: 2021-08-24 | Exp: 2041-08-19

78/1009750801Grant: 2017-09-05 | Exp: 2037-08-31

75/10012331076Grant: 2025-06-17 | Exp: 2045-06-12

75/10010519223Grant: 2019-12-31 | Exp: 2039-12-26

Formulation

(2)

75/10012303483Grant: 2025-05-20 | Exp: 2045-05-15

75/1009631016Grant: 2017-04-25 | Exp: 2037-04-20

Method of Use

(11)

95/1007416729Grant: 2008-08-26 | Exp: 2028-08-21

92/1009409984Grant: 2016-08-09 | Exp: 2036-08-04

92/1007166284Grant: 2007-01-23 | Exp: 2027-01-18

92/10010519231Grant: 2019-12-31 | Exp: 2039-12-26

92/1007179466Grant: 2007-02-20 | Exp: 2027-02-15

85/10011078267Grant: 2021-08-03 | Exp: 2041-07-29

85/1007160542Grant: 2007-01-09 | Exp: 2027-01-04

85/1008329171Grant: 2012-12-11 | Exp: 2032-12-06

85/10010259867Grant: 2019-04-16 | Exp: 2039-04-11

82/1009593310Grant: 2017-03-14 | Exp: 2037-03-09

75/1008277809Grant: 2012-10-02 | Exp: 2032-09-27

Manufacturing

(4)

85/1007736650Grant: 2010-06-15 | Exp: 2030-06-10

85/1009752125Grant: 2017-09-05 | Exp: 2037-08-31

85/1007820799Grant: 2010-10-26 | Exp: 2030-10-21

78/1008361474Grant: 2013-01-29 | Exp: 2033-01-24

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Purple Book (Biologics)

BLA 761430 | 2 presentations

351(a) ReferenceLicensedCDERInjection

Proper Name

nipocalimab-aahu

Applicant

Janssen Biotech, Inc.

Approval Date

29-Apr-25

Presentations

300MG/1.62ML (185MG/ML) — Single-Dose Vial (Intravenous)

1,200MG/6.5ML (185MG/ML) — Single-Dose Vial (Intravenous)

Source: FDA Purple Book (purplebooksearch.fda.gov).

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
May 5, 2025	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (2)

Sort:

#001 — 300MG/1.62ML(185MG/ML)

▴

INJECTABLE;INJECTION | Approved: 2025-04-29 00:00:00

No patent or exclusivity listings for this strength.

#002 — 1200MG/6.5ML(185MG/ML)

▾

INJECTABLE;INJECTION | Approved: 2025-04-29 00:00:00